House and Senate negotiators have agreed to exclude medical imaging provisions from compromise legislation that would reauthorize the State Children’s Health Insurance Program, a popular initiative than extends Medicaid benefits to children of uninsured families.
House and Senate negotiators have agreed to exclude medical imaging provisions from compromise legislation that would reauthorize the State Children's Health Insurance Program, a popular initiative than extends Medicaid benefits to children of uninsured families.House and Senate leaders announced a compromise Sept. 21. Conferees accepted most of the less costly terms of a $35 billion Senate-approved bill to fund SCHIP over five years. The House-passed Children's Health and Medicare Protection (CHAMP) Act would have increased funding to $75 billion over the next five years.
None of the Medicare provisions covered in the CHAMP Act appear in the compromise bill, according to Josh Cooper, a senior director of government relations with the American College of Radiology. Proradiology lobbyists opposed some Medicare and imaging-related provision in CHAMP, a bill sponsored by Rep. John Dingle (D-MI):
The Bush administration has proposed a $5 billion plan to continue SCHIP, an initiative it says represents a 20% funding increase. It threatened vetoes against both House and Senate reauthorization plans, saying their programs would compete against private insurance plans by extending SCHIP benefits to children in households of four with annual incomes of up to $83,000.
The Senate reauthorization plan passed with a veto-proof margin of 68 to 31. The House vote on CHAMP was 225 to 204, short of a two-thirds majority needed for a veto override.Though CHAMP's Medicare provisions are dead for now, they may be resurrected later this year when Congress considers the next round of Medicare legislation."The House already believes that they have a Medicare bill that has been voted on and passed. At the very least, the House Medicare provision from its CHAMP bill will be the starting point for any new Medicare legislation," Cooper said.For more information from the Diagnostic Imaging archive:
House, Senate conferee moves more toward CHAMP Act compromise
Bush veto threat of child insurance bill endangers imaging legislation
Radiologists brace for fallout from crisis of uninsured
FDA Grants Fast Track Designation to Emerging Agent for Brain PET Imaging
June 11th 2025Currently being evaluated in a phase 2b clinical trial, the 18F-RAD101 PET imaging agent garnered the FDA’s fast track designation for distinguishing between recurrent disease and treatment impact for brain metastases derived from solid tumors.
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.
FDA Grants Fast Track Designation to Emerging Agent for Brain PET Imaging
June 11th 2025Currently being evaluated in a phase 2b clinical trial, the 18F-RAD101 PET imaging agent garnered the FDA’s fast track designation for distinguishing between recurrent disease and treatment impact for brain metastases derived from solid tumors.
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.
2 Commerce Drive
Cranbury, NJ 08512